These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38372412)

  • 1. Pharmacogenetic considerations in therapy with novel antiplatelet and anticoagulant agents.
    Yazbeck A; Akika R; Awada Z; Zgheib NK
    Pharmacogenet Genomics; 2024 Apr; 34(3):61-72. PubMed ID: 38372412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran.
    Ross S; Paré G
    Pharmacogenomics; 2013 Oct; 14(13):1565-72. PubMed ID: 24088127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).
    O'connor CT; Kiernan TJ; Yan BP
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):725-739. PubMed ID: 28571507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel.
    Donohue MM; Tirschwell DL
    Curr Neurol Neurosci Rep; 2011 Feb; 11(1):52-60. PubMed ID: 21046289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of genetic data to guide therapy in arterial disease.
    Ross S; Nejat S; Paré G
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S281-9. PubMed ID: 26149037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding role of pharmacogenomics in the management of cardiovascular disorders.
    Yip VL; Pirmohamed M
    Am J Cardiovasc Drugs; 2013 Jun; 13(3):151-62. PubMed ID: 23579966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.
    George J; Doney A; Palmer CN; Lang CC
    Cardiovasc Ther; 2010 Jun; 28(3):135-8. PubMed ID: 20557312
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical pharmacogenomics of warfarin and clopidogrel.
    Shin J
    J Pharm Pract; 2012 Aug; 25(4):428-38. PubMed ID: 22674970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and cardiovascular disease--implications for personalized medicine.
    Johnson JA; Cavallari LH
    Pharmacol Rev; 2013 Jul; 65(3):987-1009. PubMed ID: 23686351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines.
    Bhatia K; Ladd LM; Carr KH; Di Napoli M; Saver JL; McCullough LD; Hosseini Farahabadi M; Alsbrook DL; Hinduja A; Ortiz Garcia JG; Sabbagh SY; Jafarli A; Divani AA
    Curr Neurol Neurosci Rep; 2023 May; 23(5):235-262. PubMed ID: 37037980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Occurrence of intraocular hemorrhages under monotherapy or combination therapy of antiplatelets and anticoagulants using the Japanese Adverse Drug Event Report database.
    Tanaka J; Koseki T; Sekido K; Kimata M; Ito Y; Yamada S
    J Pharm Pharm Sci; 2023; 26():11263. PubMed ID: 37122387
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiplatelet agents and anticoagulants for hypertension.
    Lip GY; Felmeden DC; Dwivedi G
    Cochrane Database Syst Rev; 2011 Dec; 2011(12):CD003186. PubMed ID: 22161375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current practices of Western Australian general dentists regarding management of patients on anticoagulant/antiplatelet therapy.
    Foo M; See L; Lee J; Feng B; Kruger E
    Aust Dent J; 2021 Dec; 66(4):385-390. PubMed ID: 34143428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
    Stehle S; Kirchheiner J; Lazar A; Fuhr U
    Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.
    Bala MM; Celinska-Lowenhoff M; Szot W; Padjas A; Kaczmarczyk M; Swierz MJ; Undas A
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012169. PubMed ID: 33045766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?
    Shahin MH; Johnson JA
    Curr Opin Cardiol; 2013 May; 28(3):305-14. PubMed ID: 23478884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke.
    Kapil N; Datta YH; Alakbarova N; Bershad E; Selim M; Liebeskind DS; Bachour O; Rao GHR; Divani AA
    Clin Appl Thromb Hemost; 2017 May; 23(4):301-318. PubMed ID: 27461564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
    Beinema M; Brouwers JR; Schalekamp T; Wilffert B
    Thromb Haemost; 2008 Dec; 100(6):1052-7. PubMed ID: 19132230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
    Hermosillo AJ; Spinler SA
    Ann Pharmacother; 2008 Jun; 42(6):790-805. PubMed ID: 18477734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of pharmacogenetics in anticoagulation therapy.
    Hill CE; Duncan A
    Clin Lab Med; 2008 Dec; 28(4):513-24. PubMed ID: 19059059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.